Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Redhill Biopharma Ltd. on June 29, 2026, covering the month of June 2026. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding a capital market transaction rather than a financial results report.
Material Changes
The primary material event disclosed is the filing of a prospectus supplement on June 29, 2026. This supplement increases the maximum aggregate offering amount of American Depositary Shares (ADS) available for issuance and sale under the At The Market Offering Agreement. Each ADS represents 10,000 ordinary shares with a par value of NIS 0.01. The agreement was originally entered into with H.C. Wainwright & Co., LLC on February 3, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard incorporation of legal opinions. The document includes legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP, along with their respective consents.
Investor Verification Checklist
- Verify the specific increase in the maximum aggregate offering amount in the attached prospectus supplement.
- Review the terms of the At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
- Confirm the current number of ADSs outstanding and the potential dilution impact of the increased offering capacity.
- Check for any subsequent filings regarding the actual issuance of shares under this expanded program.